과제정보
연구 과제 주관 기관 : Ministry of Health, Welfare & Family Affairs
참고문헌
- LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35. https://doi.org/10.1056/NEJMoa050461
- Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005;294:2437-45. https://doi.org/10.1001/jama.294.19.2437
- Arnold SV, Kosiborod M, Tang F, et al. Patterns of statin initiation, intensification, and maximization among patients hospitalized with an acute myocardial infarction. Circulation 2014;129:1303-9. https://doi.org/10.1161/CIRCULATIONAHA.113.003589
- Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 2011;305:2556-64. https://doi.org/10.1001/jama.2011.860
- Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2016;68:92-125. https://doi.org/10.1016/j.jacc.2016.03.519
- Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 2017;377:1119-31. https://doi.org/10.1056/NEJMoa1707914
- Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-89. https://doi.org/10.1016/S0140-6736(05)67528-9
- Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007;298:1180-8. https://doi.org/10.1001/jama.298.10.1180
- Kernan WN, Viscoli CM, Furie KL, et al. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med 2016;374:1321-31. https://doi.org/10.1056/NEJMoa1506930
- Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006;296:2572-81. https://doi.org/10.1001/jama.296.21.joc60158
- Saremi A, Schwenke DC, Buchanan TA, et al. Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors. Arterioscler Thromb Vasc Biol 2013;33:393-9. https://doi.org/10.1161/ATVBAHA.112.300346
- Mizoguchi M, Tahara N, Tahara A, et al. Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta. JACC Cardiovasc Imaging 2011;4:1110-8. https://doi.org/10.1016/j.jcmg.2011.08.007
- Forst T, Wilhelm B, Pfutzner A, et al. Investigation of the vascular and pleiotropic effects of atorvastatin and pioglitazone in a population at high cardiovascular risk. Diab Vasc Dis Res 2008;5:298-303. https://doi.org/10.3132/dvdr.2008.043
- Hanefeld M, Marx N, Pfutzner A, et al. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study. J Am Coll Cardiol 2007;49:290-7. https://doi.org/10.1016/j.jacc.2006.08.054
- Fayad ZA, Mani V, Woodward M, et al. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet 2011;378:1547-59. https://doi.org/10.1016/S0140-6736(11)61383-4
- Hwang BH, Kim MH, Chang K. Molecular imaging of high-risk atherosclerotic plaques: is it clinically translatable? Korean Circ J 2011;41:497-502. https://doi.org/10.4070/kcj.2011.41.9.497
- Tawakol A, Fayad ZA, Mogg R, et al. Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: results of a multicenter fluorodeoxyglucose-positron emission tomography/computed tomography feasibility study. J Am Coll Cardiol 2013;62:909-17. https://doi.org/10.1016/j.jacc.2013.04.066
- Pucci A, Formato L, Muscio M, et al. PPARgamma in coronary atherosclerosis: in vivo expression pattern and correlations with hyperlipidemic status and statin treatment. Atherosclerosis 2011;218:479-85. https://doi.org/10.1016/j.atherosclerosis.2011.06.009
- Thorp E, Kuriakose G, Shah YM, Gonzalez FJ, Tabas I. Pioglitazone increases macrophage apoptosis and plaque necrosis in advanced atherosclerotic lesions of nondiabetic low-density lipoprotein receptor-null mice. Circulation 2007;116:2182-90. https://doi.org/10.1161/CIRCULATIONAHA.107.698852
- Cocker MS, Mc Ardle B, Spence JD, et al. Imaging atherosclerosis with hybrid [18F]fluorodeoxyglucose positron emission tomography/computed tomography imaging: what Leonardo da Vinci could not see. J Nucl Cardiol 2012;19:1211-25. https://doi.org/10.1007/s12350-012-9631-9
- Rudd JH, Myers KS, Bansilal S, et al. Relationships among regional arterial inflammation, calcification, risk factors, and biomarkers: a prospective fluorodeoxyglucose positron-emission tomography/computed tomography imaging study. Circ Cardiovasc Imaging 2009;2:107-15. https://doi.org/10.1161/CIRCIMAGING.108.811752
- van der Valk FM, Verweij SL, Zwinderman KA, et al. Thresholds for arterial wall inflammation quantified by 18F-FDG PET imaging: implications for vascular interventional studies. JACC Cardiovasc Imaging 2016;9:1198-207. https://doi.org/10.1016/j.jcmg.2016.04.007
- Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J 2016;37:2999-3058. https://doi.org/10.1093/eurheartj/ehw272
- Ridker PM, Luscher TF. Anti-inflammatory therapies for cardiovascular disease. Eur Heart J 2014;35:1782-91. https://doi.org/10.1093/eurheartj/ehu203
- Erdmann E, Dormandy JA, Charbonnel B, et al. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol 2007;49:1772-80. https://doi.org/10.1016/j.jacc.2006.12.048
- Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass CK. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest 2000;106:523-31. https://doi.org/10.1172/JCI10370
- Chang K, Francis SA, Aikawa E, et al. Pioglitazone suppresses inflammation in vivo in murine carotid atherosclerosis: novel detection by dual-target fluorescence molecular imaging. Arterioscler Thromb Vasc Biol 2010;30:1933-9. https://doi.org/10.1161/ATVBAHA.110.206342
- Koh KK, Sakuma I, Shimada K, Hayashi T, Quon MJ. Combining potent statin therapy with other drugs to optimize simultaneous cardiovascular and metabolic benefits while minimizing adverse events. Korean Circ J 2017;47:432-9. https://doi.org/10.4070/kcj.2016.0406
피인용 문헌
- Imaging Atherosclerosis by PET, With Emphasis on the Role of FDG and NaF as Potential Biomarkers for This Disorder vol.11, pp.None, 2020, https://doi.org/10.3389/fphys.2020.511391
- Atherosclerosis imaging using PET: Insights and applications vol.178, pp.11, 2018, https://doi.org/10.1111/bph.14868
- Advances in Radiopharmaceutical Sciences for Vascular Inflammation Imaging: Focus on Clinical Applications vol.26, pp.23, 2021, https://doi.org/10.3390/molecules26237111